New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing Biogen also debuted […]
Insurance giant fined 10.6m for balance sheet errors before Aviva takeover
...
Read moreDetails
